Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 56 entries
Sorted by: Best Match Show Resources per page
Chitosan-covered calcium phosphate particles as a drug vehicle for delivery to the eye.

Nanomedicine : nanotechnology, biology, and medicine

Popova EV, Tikhomirova VE, Beznos OV, Chesnokova NB, Grigoriev YV, Klyachko NL, Kost OA.
PMID: 34775060
Nanomedicine. 2021 Nov 12;40:102493. doi: 10.1016/j.nano.2021.102493. Epub 2021 Nov 12.

Formulations on the base of an inhibitor of angiotensin-converting enzyme, enalaprilat, were prepared by the inclusion of the drug into calcium phosphate (CaP)-particles in situ, followed by the covering of the particles with 5 kDa chitosan or 72 kDa...

Cite
Popova EV, Tikhomirova VE, Beznos OV, et al. Chitosan-covered calcium phosphate particles as a drug vehicle for delivery to the eye. Nanomedicine. 2021;40:102493doi: 10.1016/j.nano.2021.102493.
Popova, E. V., Tikhomirova, V. E., Beznos, O. V., Chesnokova, N. B., Grigoriev, Y. V., Klyachko, N. L., & Kost, O. A. (2021). Chitosan-covered calcium phosphate particles as a drug vehicle for delivery to the eye. Nanomedicine : nanotechnology, biology, and medicine, 40102493. https://doi.org/10.1016/j.nano.2021.102493
Popova, Ekaterina V, et al. "Chitosan-covered calcium phosphate particles as a drug vehicle for delivery to the eye." Nanomedicine : nanotechnology, biology, and medicine vol. 40 (2021): 102493. doi: https://doi.org/10.1016/j.nano.2021.102493
Popova EV, Tikhomirova VE, Beznos OV, Chesnokova NB, Grigoriev YV, Klyachko NL, Kost OA. Chitosan-covered calcium phosphate particles as a drug vehicle for delivery to the eye. Nanomedicine. 2021 Nov 12;40:102493. doi: 10.1016/j.nano.2021.102493. Epub 2021 Nov 12. PMID: 34775060.
Copy Download .nbib Format: NLM
Chitosan-covered calcium phosphate particles as a drug vehicle for delivery to the eye.

Nanomedicine : nanotechnology, biology, and medicine

Popova EV, Tikhomirova VE, Beznos OV, Chesnokova NB, Grigoriev YV, Klyachko NL, Kost OA.
PMID: 34775060
Nanomedicine. 2021 Nov 12;40:102493. doi: 10.1016/j.nano.2021.102493. Epub 2021 Nov 12.

Formulations on the base of an inhibitor of angiotensin-converting enzyme, enalaprilat, were prepared by the inclusion of the drug into calcium phosphate (CaP)-particles in situ, followed by the covering of the particles with 5 kDa chitosan or 72 kDa...

Cite
Popova EV, Tikhomirova VE, Beznos OV, et al. Chitosan-covered calcium phosphate particles as a drug vehicle for delivery to the eye. Nanomedicine. 2021;40:102493doi: 10.1016/j.nano.2021.102493.
Popova, E. V., Tikhomirova, V. E., Beznos, O. V., Chesnokova, N. B., Grigoriev, Y. V., Klyachko, N. L., & Kost, O. A. (2021). Chitosan-covered calcium phosphate particles as a drug vehicle for delivery to the eye. Nanomedicine : nanotechnology, biology, and medicine, 40102493. https://doi.org/10.1016/j.nano.2021.102493
Popova, Ekaterina V, et al. "Chitosan-covered calcium phosphate particles as a drug vehicle for delivery to the eye." Nanomedicine : nanotechnology, biology, and medicine vol. 40 (2021): 102493. doi: https://doi.org/10.1016/j.nano.2021.102493
Popova EV, Tikhomirova VE, Beznos OV, Chesnokova NB, Grigoriev YV, Klyachko NL, Kost OA. Chitosan-covered calcium phosphate particles as a drug vehicle for delivery to the eye. Nanomedicine. 2021 Nov 12;40:102493. doi: 10.1016/j.nano.2021.102493. Epub 2021 Nov 12. PMID: 34775060.
Copy Download .nbib Format: NLM
Clinical Pharmacokinetics of Enalapril and Enalaprilat in Pediatric Patients-A Systematic Review.

Frontiers in pediatrics

Faisal M, Cawello W, Laeer S.
PMID: 33643971
Front Pediatr. 2021 Feb 12;9:611322. doi: 10.3389/fped.2021.611322. eCollection 2021.

No abstract available.

Cite
Faisal M, Cawello W, Laeer S. Clinical Pharmacokinetics of Enalapril and Enalaprilat in Pediatric Patients-A Systematic Review. Front Pediatr. 2021;9:611322doi: 10.3389/fped.2021.611322.
Faisal, M., Cawello, W., Laeer, S. (2021). Clinical Pharmacokinetics of Enalapril and Enalaprilat in Pediatric Patients-A Systematic Review. Frontiers in pediatrics, 9611322. https://doi.org/10.3389/fped.2021.611322
Faisal, Muhammad, et al. "Clinical Pharmacokinetics of Enalapril and Enalaprilat in Pediatric Patients-A Systematic Review." Frontiers in pediatrics vol. 9 (2021): 611322. doi: https://doi.org/10.3389/fped.2021.611322
Faisal M, Cawello W, Laeer S. Clinical Pharmacokinetics of Enalapril and Enalaprilat in Pediatric Patients-A Systematic Review. Front Pediatr. 2021 Feb 12;9:611322. doi: 10.3389/fped.2021.611322. eCollection 2021. PMID: 33643971; PMCID: PMC7907604.
Copy Download .nbib Format: NLM
Regional Intestinal Drug Permeability and Effects of Permeation Enhancers in Rat.

Pharmaceutics

Dahlgren D, Cano-Cebrián MJ, Olander T, Hedeland M, Sjöblom M, Lennernäs H.
PMID: 32182653
Pharmaceutics. 2020 Mar 08;12(3). doi: 10.3390/pharmaceutics12030242.

Sufficient colonic absorption is necessary for all systemically acting drugs in dosage forms that release the drug in the large intestine. Preclinically, colonic absorption is often investigated using the rat single-pass intestinal perfusion model. This model can determine intestinal...

Cite
Dahlgren D, Cano-Cebrián MJ, Olander T, et al. Regional Intestinal Drug Permeability and Effects of Permeation Enhancers in Rat. Pharmaceutics. 2020;12(3)doi: 10.3390/pharmaceutics12030242.
Dahlgren, D., Cano-Cebrián, M. J., Olander, T., Hedeland, M., Sjöblom, M., & Lennernäs, H. (2020). Regional Intestinal Drug Permeability and Effects of Permeation Enhancers in Rat. Pharmaceutics, 12(3), . https://doi.org/10.3390/pharmaceutics12030242
Dahlgren, David, et al. "Regional Intestinal Drug Permeability and Effects of Permeation Enhancers in Rat." Pharmaceutics vol. 12,3 (2020). doi: https://doi.org/10.3390/pharmaceutics12030242
Dahlgren D, Cano-Cebrián MJ, Olander T, Hedeland M, Sjöblom M, Lennernäs H. Regional Intestinal Drug Permeability and Effects of Permeation Enhancers in Rat. Pharmaceutics. 2020 Mar 08;12(3). doi: 10.3390/pharmaceutics12030242. PMID: 32182653; PMCID: PMC7150977.
Copy Download .nbib Format: NLM
Simultaneous Semi-Mechanistic Population Pharmacokinetic Modeling Analysis of Enalapril and Enalaprilat Serum and Urine Concentrations From Child Appropriate Orodispersible Minitablets.

Frontiers in pediatrics

Faisal M, Cawello W, Burckhardt BB, de Hoon J, Laer S.
PMID: 31338356
Front Pediatr. 2019 Jul 09;7:281. doi: 10.3389/fped.2019.00281. eCollection 2019.

Enalapril is recommended as the first line of therapy and is proven to improve survival rates for treatment of Pediatric Heart Failure; however, an approved drug and child appropriate dosage formulation is still absent. The present analysis was conducted...

Cite
Faisal M, Cawello W, Burckhardt BB, et al. Simultaneous Semi-Mechanistic Population Pharmacokinetic Modeling Analysis of Enalapril and Enalaprilat Serum and Urine Concentrations From Child Appropriate Orodispersible Minitablets. Front Pediatr. 2019;7:281doi: 10.3389/fped.2019.00281.
Faisal, M., Cawello, W., Burckhardt, B. B., de Hoon, J., Laer, S. (2019). Simultaneous Semi-Mechanistic Population Pharmacokinetic Modeling Analysis of Enalapril and Enalaprilat Serum and Urine Concentrations From Child Appropriate Orodispersible Minitablets. Frontiers in pediatrics, 7281. https://doi.org/10.3389/fped.2019.00281
Faisal, Muhammad, et al. "Simultaneous Semi-Mechanistic Population Pharmacokinetic Modeling Analysis of Enalapril and Enalaprilat Serum and Urine Concentrations From Child Appropriate Orodispersible Minitablets." Frontiers in pediatrics vol. 7 (2019): 281. doi: https://doi.org/10.3389/fped.2019.00281
Faisal M, Cawello W, Burckhardt BB, de Hoon J, Laer S. Simultaneous Semi-Mechanistic Population Pharmacokinetic Modeling Analysis of Enalapril and Enalaprilat Serum and Urine Concentrations From Child Appropriate Orodispersible Minitablets. Front Pediatr. 2019 Jul 09;7:281. doi: 10.3389/fped.2019.00281. eCollection 2019. PMID: 31338356; PMCID: PMC6629781.
Copy Download .nbib Format: NLM
Effect of CES1 genetic variation on enalapril steady-state pharmacokinetics and pharmacodynamics in healthy subjects.

British journal of clinical pharmacology

Her LH, Wang X, Shi J, Choi HJ, Jung SM, Smith LS, Wu AH, Bleske BE, Zhu HJ.
PMID: 33963573
Br J Clin Pharmacol. 2021 May 07; doi: 10.1111/bcp.14888. Epub 2021 May 07.

AIMS: Enalapril is a prodrug and needs to be activated by carboxylesterase 1 (CES1). A previous in vitro study demonstrated the CES1 genetic variant, G143E (rs71647871), significantly impaired enalapril activation. Two previous clinical studies examined the impact of G143E...

Cite
Her LH, Wang X, Shi J, et al. Effect of CES1 genetic variation on enalapril steady-state pharmacokinetics and pharmacodynamics in healthy subjects. Br J Clin Pharmacol. 2021;doi: 10.1111/bcp.14888.
Her, L. H., Wang, X., Shi, J., Choi, H. J., Jung, S. M., Smith, L. S., Wu, A. H., Bleske, B. E., & Zhu, H. J. (2021). Effect of CES1 genetic variation on enalapril steady-state pharmacokinetics and pharmacodynamics in healthy subjects. British journal of clinical pharmacology, . https://doi.org/10.1111/bcp.14888
Her, Lucy H, et al. "Effect of CES1 genetic variation on enalapril steady-state pharmacokinetics and pharmacodynamics in healthy subjects." British journal of clinical pharmacology vol. (2021). doi: https://doi.org/10.1111/bcp.14888
Her LH, Wang X, Shi J, Choi HJ, Jung SM, Smith LS, Wu AH, Bleske BE, Zhu HJ. Effect of CES1 genetic variation on enalapril steady-state pharmacokinetics and pharmacodynamics in healthy subjects. Br J Clin Pharmacol. 2021 May 07; doi: 10.1111/bcp.14888. Epub 2021 May 07. PMID: 33963573.
Copy Download .nbib Format: NLM
Intravenous enalaprilat for treatment of acute hypertensive heart failure in the emergency department.

International journal of emergency medicine

Ayaz SI, Sharkey CM, Kwiatkowski GM, Wilson SS, John RS, Tolomello R, Mahajan A, Millis S, Levy PD.
PMID: 28032307
Int J Emerg Med. 2016 Dec;9(1):28. doi: 10.1186/s12245-016-0125-4. Epub 2016 Dec 28.

BACKGROUND: Afterload reduction with bolus enalaprilat is used by some for management of acute hypertensive heart failure (HF) but existing data on the safety and effectiveness of this practice are limited. The purpose of this study was to evaluate...

Cite
Ayaz SI, Sharkey CM, Kwiatkowski GM, et al. Intravenous enalaprilat for treatment of acute hypertensive heart failure in the emergency department. Int J Emerg Med. 2016;9(1):28doi: 10.1186/s12245-016-0125-4.
Ayaz, S. I., Sharkey, C. M., Kwiatkowski, G. M., Wilson, S. S., John, R. S., Tolomello, R., Mahajan, A., Millis, S., & Levy, P. D. (2016). Intravenous enalaprilat for treatment of acute hypertensive heart failure in the emergency department. International journal of emergency medicine, 9(1), 28. https://doi.org/10.1186/s12245-016-0125-4
Ayaz, Syed Imran, et al. "Intravenous enalaprilat for treatment of acute hypertensive heart failure in the emergency department." International journal of emergency medicine vol. 9,1 (2016): 28. doi: https://doi.org/10.1186/s12245-016-0125-4
Ayaz SI, Sharkey CM, Kwiatkowski GM, Wilson SS, John RS, Tolomello R, Mahajan A, Millis S, Levy PD. Intravenous enalaprilat for treatment of acute hypertensive heart failure in the emergency department. Int J Emerg Med. 2016 Dec;9(1):28. doi: 10.1186/s12245-016-0125-4. Epub 2016 Dec 28. PMID: 28032307; PMCID: PMC5195922.
Copy Download .nbib Format: NLM
ACE Inhibitors and Renal Vascular Responses in the Spontaneously Hypertensive Rat.

Journal of cardiovascular pharmacology and therapeutics

Hollenberg NK, Guidi E.
PMID: 10684494
J Cardiovasc Pharmacol Ther. 1998 Apr;3(2):161-170. doi: 10.1177/107424849800300209.

BACKGROUND: Substantial evidence has accumulated for the intrarenal generation of functionally important quantities of angiotensin II (Ang II). To assess the possibility that Ang II generation occurs beyond a barrier to diffusion from the vascular compartment, six angiotensin-converting enzyme...

Cite
Hollenberg NK, Guidi E. ACE Inhibitors and Renal Vascular Responses in the Spontaneously Hypertensive Rat. J Cardiovasc Pharmacol Ther. 1998;3(2):161-170doi: 10.1177/107424849800300209.
Hollenberg, N. K., & Guidi, E. (1998). ACE Inhibitors and Renal Vascular Responses in the Spontaneously Hypertensive Rat. Journal of cardiovascular pharmacology and therapeutics, 3(2), 161-170. https://doi.org/10.1177/107424849800300209
Hollenberg, and Guidi. "ACE Inhibitors and Renal Vascular Responses in the Spontaneously Hypertensive Rat." Journal of cardiovascular pharmacology and therapeutics vol. 3,2 (1998): 161-170. doi: https://doi.org/10.1177/107424849800300209
Hollenberg NK, Guidi E. ACE Inhibitors and Renal Vascular Responses in the Spontaneously Hypertensive Rat. J Cardiovasc Pharmacol Ther. 1998 Apr;3(2):161-170. doi: 10.1177/107424849800300209. PMID: 10684494.
Copy Download .nbib Format: NLM
Effects of Enalaprilat on Regional Wall Stress in Patients with Angina Pectoris.

American journal of therapeutics

González-Fernández RA, Altieri PI, Banchs HL, Escobales N.
PMID: 11850683
Am J Ther. 1995 Jun;2(6):395-400.

Left ventricle (LV) cineventriculograms silhouettes in the right anterior oblique projection with simultaneous pressure micromanometry were assessed before and 10 min after administration of 1.25 mg enalaprilat intravenously to 10 patients with angina pectoris undergoing diagnostic cardiac catheterization. Cineventriculograms...

Cite
González-Fernández RA, Altieri PI, Banchs HL, et al. Effects of Enalaprilat on Regional Wall Stress in Patients with Angina Pectoris. Am J Ther. 1995;2(6):395-400
González-Fernández, R. A., Altieri, P. I., Banchs, H. L., & Escobales, N. (1995). Effects of Enalaprilat on Regional Wall Stress in Patients with Angina Pectoris. American journal of therapeutics, 2(6), 395-400.
González-Fernández, Robert A., et al. "Effects of Enalaprilat on Regional Wall Stress in Patients with Angina Pectoris." American journal of therapeutics vol. 2,6 (1995): 395-400.
González-Fernández RA, Altieri PI, Banchs HL, Escobales N. Effects of Enalaprilat on Regional Wall Stress in Patients with Angina Pectoris. Am J Ther. 1995 Jun;2(6):395-400. PMID: 11850683.
Copy Download .nbib Format: NLM
Measurement of Bradykinin Formation and Degradation in Blood Plasma: Relevance for Acquired Angioedema Associated With Angiotensin Converting Enzyme Inhibition and for Hereditary Angioedema Due to Factor XII or Plasminogen Gene Variants.

Frontiers in medicine

Marceau F, Rivard GE, Gauthier JM, Binkley KE, Bonnefoy A, Boccon-Gibod I, Bouillet L, Picard M, Levesque G, Elfassy HL, Bachelard H, Hébert J, Bork K.
PMID: 32766265
Front Med (Lausanne). 2020 Jul 17;7:358. doi: 10.3389/fmed.2020.00358. eCollection 2020.

Bradykinin (BK)-mediated angioedema (AE) states are rare acquired or hereditary conditions involving localized edema of the subcutaneous and submucosal tissues. Citrated plasma from healthy volunteers or patients with hereditary angioedema (HAE) with normal level of C1-inhibitor (C1-INH) was used...

Cite
Marceau F, Rivard GE, Gauthier JM, et al. Measurement of Bradykinin Formation and Degradation in Blood Plasma: Relevance for Acquired Angioedema Associated With Angiotensin Converting Enzyme Inhibition and for Hereditary Angioedema Due to Factor XII or Plasminogen Gene Variants. Front Med (Lausanne). 2020;7:358doi: 10.3389/fmed.2020.00358.
Marceau, F., Rivard, G. E., Gauthier, J. M., Binkley, K. E., Bonnefoy, A., Boccon-Gibod, I., Bouillet, L., Picard, M., Levesque, G., Elfassy, H. L., Bachelard, H., Hébert, J., & Bork, K. (2020). Measurement of Bradykinin Formation and Degradation in Blood Plasma: Relevance for Acquired Angioedema Associated With Angiotensin Converting Enzyme Inhibition and for Hereditary Angioedema Due to Factor XII or Plasminogen Gene Variants. Frontiers in medicine, 7358. https://doi.org/10.3389/fmed.2020.00358
Marceau, François, et al. "Measurement of Bradykinin Formation and Degradation in Blood Plasma: Relevance for Acquired Angioedema Associated With Angiotensin Converting Enzyme Inhibition and for Hereditary Angioedema Due to Factor XII or Plasminogen Gene Variants." Frontiers in medicine vol. 7 (2020): 358. doi: https://doi.org/10.3389/fmed.2020.00358
Marceau F, Rivard GE, Gauthier JM, Binkley KE, Bonnefoy A, Boccon-Gibod I, Bouillet L, Picard M, Levesque G, Elfassy HL, Bachelard H, Hébert J, Bork K. Measurement of Bradykinin Formation and Degradation in Blood Plasma: Relevance for Acquired Angioedema Associated With Angiotensin Converting Enzyme Inhibition and for Hereditary Angioedema Due to Factor XII or Plasminogen Gene Variants. Front Med (Lausanne). 2020 Jul 17;7:358. doi: 10.3389/fmed.2020.00358. eCollection 2020. PMID: 32766265; PMCID: PMC7380097.
Copy Download .nbib Format: NLM
Advances in screening for membrane permeability: high-resolution PAMPA for medicinal chemists.

Drug discovery today. Technologies

Kansy M, Avdeef A, Fischer H.
PMID: 24981614
Drug Discov Today Technol. 2004 Dec;1(4):349-55. doi: 10.1016/j.ddtec.2004.11.013.

The majority of orally administered drugs are described to be passively transported across the lipophilic cell membranes [Lennernäs, H. et al. (1994) Intestinal drug absorption during induced net water absorption in human; a mechanistic study using antipyrine, atenolol and...

Cite
Kansy M, Avdeef A, Fischer H. Advances in screening for membrane permeability: high-resolution PAMPA for medicinal chemists. Drug Discov Today Technol. 2004;1(4):349-55doi: 10.1016/j.ddtec.2004.11.013.
Kansy, M., Avdeef, A., & Fischer, H. (2004). Advances in screening for membrane permeability: high-resolution PAMPA for medicinal chemists. Drug discovery today. Technologies, 1(4), 349-55. https://doi.org/10.1016/j.ddtec.2004.11.013
Kansy, Manfred, et al. "Advances in screening for membrane permeability: high-resolution PAMPA for medicinal chemists." Drug discovery today. Technologies vol. 1,4 (2004): 349-55. doi: https://doi.org/10.1016/j.ddtec.2004.11.013
Kansy M, Avdeef A, Fischer H. Advances in screening for membrane permeability: high-resolution PAMPA for medicinal chemists. Drug Discov Today Technol. 2004 Dec;1(4):349-55. doi: 10.1016/j.ddtec.2004.11.013. PMID: 24981614.
Copy Download .nbib Format: NLM
LC-MS/MS assay for quantitation of enalapril and enalaprilat in plasma for bioequivalence study in Indian subjects.

Future science OA

Halder D, Dan S, Pal MM, Biswas E, Chatterjee N, Sarkar P, Halder UC, Pal TK.
PMID: 28344828
Future Sci OA. 2017 Feb 02;3(1):FSO165. doi: 10.4155/fsoa-2016-0071. eCollection 2017 Mar.

BACKGROUND: Enalapril (EPL) is an angiotensin-converting enzyme inhibitor for the treatment of hypertension and chronic heart failure. Enalaprilat (EPLT) is an active metabolite that contributes to the overall activity of EPL.AIM: To quantitate EPL along with its metabolite EPLT...

Cite
Halder D, Dan S, Pal MM, et al. LC-MS/MS assay for quantitation of enalapril and enalaprilat in plasma for bioequivalence study in Indian subjects. Future Sci OA. 2017;3(1):FSO165doi: 10.4155/fsoa-2016-0071.
Halder, D., Dan, S., Pal, M. M., Biswas, E., Chatterjee, N., Sarkar, P., Halder, U. C., & Pal, T. K. (2017). LC-MS/MS assay for quantitation of enalapril and enalaprilat in plasma for bioequivalence study in Indian subjects. Future science OA, 3(1), FSO165. https://doi.org/10.4155/fsoa-2016-0071
Halder, Dhiman, et al. "LC-MS/MS assay for quantitation of enalapril and enalaprilat in plasma for bioequivalence study in Indian subjects." Future science OA vol. 3,1 (2017): FSO165. doi: https://doi.org/10.4155/fsoa-2016-0071
Halder D, Dan S, Pal MM, Biswas E, Chatterjee N, Sarkar P, Halder UC, Pal TK. LC-MS/MS assay for quantitation of enalapril and enalaprilat in plasma for bioequivalence study in Indian subjects. Future Sci OA. 2017 Feb 02;3(1):FSO165. doi: 10.4155/fsoa-2016-0071. eCollection 2017 Mar. PMID: 28344828; PMCID: PMC5351712.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 56 entries